Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91

Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce that Analysguiden has published a detailed research report analysing the company’s recent progress and setting a price target of SEK 91.

The report provides an independent assessment of ExpreS2ion’s development pipeline and strategic initiatives, focusing on the approval to initiate a Phase I clinical trial for the company’s HER2-targeted therapeutic breast cancer vaccine, ES2B-C001.

Key highlights from the report include:

• Progress in Clinical Development: The approval by the Austrian Agency for Health and Food Safety (BASG) to start the Phase I trial for ES2B-C001 marks a critical milestone for ExpreS2ion’s pipeline.

• Market Potential for ES2B-C001: The report discusses the potential for ES2B-C001 to address unmet needs in HER2-positive metastatic breast cancer and estimates a possible market opportunity exceeding EUR 3 billion if development is successful.

• Strategic and Financial Insights: Analysguiden outlines ExpreS2ion’s ability to leverage its proprietary ExpreS2 platform and its financial positioning to progress its pipeline and seek partnerships.

The full Analysguiden report, along with previously published analyst reports about ExpreS2ion, is available on the company’s investor website here: Analyst Reports.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com 

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.